医学
经皮冠状动脉介入治疗
传统PCI
内科学
心肌梗塞
危险系数
置信区间
心脏病学
比例危险模型
临床终点
外科
临床试验
作者
Haoming He,Yi-nong Chen,Jilang Zeng,Shuwen Zheng,Longyang Zhu,Zhe Wang,Siqi Jiao,Fu-rong Yang,Yihong Sun
出处
期刊:Thrombosis and Haemostasis
[Georg Thieme Verlag KG]
日期:2023-08-29
被引量:2
标识
DOI:10.1055/s-0043-1773764
摘要
Background The Age–D-dimer–Albumin (ADA), the CREDO-Kyoto, and the PARIS scores have been established to predict thrombotic events. However, the prognostic performance of these scores compared to the GRACE score in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) has not been reported. Methods Consecutive AMI patients treated with PCI were retrospectively enrolled at a teaching hospital in China from January 2016 to December 2019. The primary endpoint was all-cause mortality and the secondary endpoint was cardiac death. Harrell's C-index and net reclassification improvement (NRI) were used to compare the prognostic value of these scores with the GRACE score for mortality. Results Of the 1,578 patients enrolled, the mean age was 62.5 years, and 23.5% were female. During a median follow-up of 3.8 years, 146 all-cause deaths and 80 cardiac deaths occurred. The ADA score showed a better prognostic performance than the GRACE (Harrell's C-index: 0.800 vs. 0.749; p = 0.003), the CREDO-Kyoto (Harrell's C-index: 0.800 vs. 0.765; NRI = 0.348, p < 0.001), and the PARIS scores (Harrell's C-index: 0.800 vs. 0.694; NRI = 0.556, p < 0.001). In the multivariable Cox regression analysis, the ADA score was independently associated with all-cause mortality (hazard ratio [HR] = 1.641 per 10-point increment, 95% confidence interval [CI]: 1.397–1.929) and cardiac death (HR = 1.636 per 10-point increment, 95% CI: 1.325–2.020). The risk of all-cause mortality and cardiac death increased with the rising of the ADA score. Conclusion The ADA score showed a better prognostic performance than the GRACE, the CREDO-Kyoto, and the PARIS scores in patients with AMI undergoing PCI, which was a potential predictive tool for mortality.
科研通智能强力驱动
Strongly Powered by AbleSci AI